A Clinical Indicator-based Prognostic Model Predicting Treatment Outcomes of Pulmonary Tuberculosis: a Prospective Cohort Study

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2023 Feb 21

PMID 36803117

Authors

Mengyao Zhan

Hao Xue

Yuting Wang

Zhuchao Wu

Qin Wen

Xinling Shi

Jianming Wang

Affiliations

Soon will be listed here.

Abstract

Objectives: Identifying prognostic factors helps optimize the treatment regimen and promote favorable outcomes. We conducted a prospective cohort study on patients with pulmonary tuberculosis to construct a clinical indicator-based model and estimate its performance.

Methods: We performed a two-stage study by recruiting 346 pulmonary tuberculosis patients diagnosed between 2016 and 2018 in Dafeng city as the training cohort and 132 patients diagnosed between 2018 and 2019 in Nanjing city as the external validation population. We generated a risk score based on blood and biochemistry examination indicators by the least absolute shrinkage and selection operator (LASSO) Cox regression. Univariate and multivariate Cox regression models were used to assess the risk score, and the strength of association was expressed as the hazard ratio (HR) and 95% confidence interval (CI). We plotted the receiver operating characteristic (ROC) curve and calculated the area under the curve (AUC). Internal validation was conducted by 10-fold cross-validation.

Results: Ten significant indicators (PLT, PCV, LYMPH, MONO%, NEUT, NEUT%, TBTL, ALT, UA, and Cys-C) were selected to generate the risk score. Clinical indicator-based score (HR: 10.018, 95% CI: 4.904-20.468, P < 0.001), symptom-based score (HR: 1.356, 95% CI: 1.079-1.704, P = 0.009), pulmonary cavity (HR: 0.242, 95% CI: 0.087-0.674, P = 0.007), treatment history (HR: 2.810, 95% CI: 1.137-6.948, P = 0.025), and tobacco smoking (HR: 2.499, 95% CI: 1.097-5.691, P = 0.029) were significantly related to the treatment outcomes. The AUC was 0.766 (95% CI: 0.649-0.863) in the training cohort and 0.796 (95% CI: 0.630-0.928) in the validation dataset.

Conclusion: In addition to the traditional predictive factors, the clinical indicator-based risk score determined in this study has a good prediction effect on the prognosis of tuberculosis.

References

Qiu F, Liang C, Liu H, Zeng Y, Hou S, Huang S . Impacts of cigarette smoking on immune responsiveness: Up and down or upside down?. Oncotarget. 2016; 8(1):268-284. PMC: 5352117. DOI: 10.18632/oncotarget.13613. View

. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000; 49(RR-6):1-51. View

Panjabi R, Comstock G, Golub J . Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis. 2007; 11(8):828-37. View

Kim C, Kim Y, Bae J, Kim A, Kim J, Son H . Risk factors of delayed isolation of patients with pulmonary tuberculosis. Clin Microbiol Infect. 2020; 26(8):1058-1062. DOI: 10.1016/j.cmi.2020.01.032. View

Lin H, Ezzati M, Murray M . Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med. 2007; 4(1):e20. PMC: 1769410. DOI: 10.1371/journal.pmed.0040020. View

Borisov A, Morris S, Njie G, Winston C, Burton D, Goldberg S . Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection. MMWR Morb Mortal Wkly Rep. 2018; 67(25):723-726. PMC: 6023184. DOI: 10.15585/mmwr.mm6725a5. View

Ralph A, Ardian M, Wiguna A, Maguire G, Becker N, Drogumuller G . A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax. 2010; 65(10):863-9. DOI: 10.1136/thx.2010.136242. View

Burusie A, Enquesilassie F, Addissie A, Dessalegn B, Lamaro T . Effect of smoking on tuberculosis treatment outcomes: A systematic review and meta-analysis. PLoS One. 2020; 15(9):e0239333. PMC: 7498109. DOI: 10.1371/journal.pone.0239333. View

Horita N, Miyazawa N, Yoshiyama T, Sato T, Yamamoto M, Tomaru K . Development and validation of a tuberculosis prognostic score for smear-positive in-patients in Japan. Int J Tuberc Lung Dis. 2012; 17(1):54-60. DOI: 10.5588/ijtld.12.0476. View

10.

Lan N, Lien H, Tung L, Borgdorff M, Kremer K, van Soolingen D . Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam. Emerg Infect Dis. 2004; 9(12):1633-5. PMC: 3034339. DOI: 10.3201/eid0912.030169. View

11.

Peetluk L, Rebeiro P, Ridolfi F, Andrade B, Cordeiro-Santos M, Kritski A . A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment Outcomes. Clin Infect Dis. 2021; 74(6):973-982. PMC: 8946703. DOI: 10.1093/cid/ciab598. View

12.

Pefura-Yone E, Balkissou A, Poka-Mayap V, Fatime-Abaicho H, Enono-Edende P, Kengne A . Development and validation of a prognostic score during tuberculosis treatment. BMC Infect Dis. 2017; 17(1):251. PMC: 5385091. DOI: 10.1186/s12879-017-2309-9. View

13.

Luo Y, Tang G, Yuan X, Lin Q, Mao L, Song H . Combination of Blood Routine Examination and T-SPOT.TB Assay for Distinguishing Between Active Tuberculosis and Latent Tuberculosis Infection. Front Cell Infect Microbiol. 2021; 11:575650. PMC: 8279757. DOI: 10.3389/fcimb.2021.575650. View

14.

Stefanescu S, Cocos R, Turcu-Stiolica A, Shelby E, Matei M, Subtirelu M . Prediction of Treatment Outcome with Inflammatory Biomarkers after 2 Months of Therapy in Pulmonary Tuberculosis Patients: Preliminary Results. Pathogens. 2021; 10(7). PMC: 8308673. DOI: 10.3390/pathogens10070789. View

15.

Fitzpatrick L, Okwera A, Mugerwa R, Ridzon R, Ehiner J, Onorato I . An investigation of suspected exogenous reinfection in tuberculosis patients in Kampala, Uganda. Int J Tuberc Lung Dis. 2002; 6(6):550-2. DOI: 10.5588/09640569513084. View

16.

Liang Y, Ma Y, Huang K, Luo H, Wang A, Xiong Z . [The clinical application of blood routine and liver and kidney function test in COVID-19 disease prediction]. Zhonghua Yu Fang Yi Xue Za Zhi. 2021; 55(1):89-95. DOI: 10.3760/cma.j.cn112150-20200629-00947. View

17.

Blazek K, van Zwieten A, Saglimbene V, Teixeira-Pinto A . A practical guide to multiple imputation of missing data in nephrology. Kidney Int. 2020; 99(1):68-74. DOI: 10.1016/j.kint.2020.07.035. View

18.

Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D . Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2016; 17(2):223-234. DOI: 10.1016/S1473-3099(16)30407-8. View

19.

Lui G, Wong R, Li F, Lee M, Lai R, Li T . High mortality in adults hospitalized for active tuberculosis in a low HIV prevalence setting. PLoS One. 2014; 9(3):e92077. PMC: 3958438. DOI: 10.1371/journal.pone.0092077. View

20.

Nagai K, Horita N, Sato T, Yamamoto M, Nagakura H, Kaneko T . Age, Dehydration, Respiratory Failure, Orientation Disturbance, and Blood Pressure Score Predicts In-hospital Mortality in HIV-negative Non-multidrug-resistant Smear-positive Pulmonary Tuberculosis in Japan. Sci Rep. 2016; 6:21610. PMC: 4756351. DOI: 10.1038/srep21610. View